Description (Abstract)
Sale of all interest in assets related to development, non-clinical and clinical studies, manufacture, formulation, testing, use, distribution, marketing, sale, promotion and other commercialization and exploitation of products containing the SD-101 toll like receptor 9 agonist compound, including patents, trademarks, trade names, domain names, copyrights, data, trade secrets, know-how, processes, software, improvements, goodwill, permits, contracts, inventory, regulatory documentation and other related assets.
Citation
RoyaltyStat 2023, Asset Purchase Agreement, L40273. https://doi.org/10.34675/L40273
Please contact us for more information.
